Table 2 Examples of targeted therapies currently undergoing clinical testing in NSCLC
Study name/identifiera | Purpose | Targeted therapies |
|---|---|---|
Pilot trial of molecular profiling and targeted therapy for advanced NSCLC, SCLC, and thymic malignancies NCT01306045 | Evaluate the ability of genetic analysis to determine targeted therapy for patients with NSCLC | AZD6244 MEK1 inhibitor for KRAS or BRAF mutations |
MK-2206 AKT inhibitor for PIK3CA, AKT, PTEN mutations | ||
Sunitib inhibitor for KIT or PDGFRA mutations | ||
Lapatinib inhibitor for ERBB2 | ||
Erlotinib inhibitor for EGFR mutations | ||
Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic NSCLC NCT02117167 | Evaluate the use of high throughput genome analysis to determine administration of targeted therapy according to genetic profile of the tumor compared to standard treatment. Randomized multicenter Phase II trial | AZD2014 inhibitor for m-TOR |
AZD4547 inhibitor for FGFR | ||
AZD5363 inhibitor for AKT, | ||
AZD8931 inhibitor for EGFR | ||
Selumetinib inhibitor for MEK1 | ||
Vandetanib inhibitor for VEGFR and EGFR | ||
FGFR1 amplification as a predictor of efficacy in a biomarker-driven phase II study of BIBF 1120 in advanced lung SCC patients who have failed up to 2 prior chemotherapeutic regimens NCT01948141 | Evaluate efficacy of nintedanib in treating patients with advanced NSCLC who failed up to two previous chemotherapy regimens and use of FGFR1 gene copy number is a predictive biomarker | Nintedanib TKI for FGFR1 |